Skip to main content
. 2014 Oct 8;148(2):403–414.e7. doi: 10.1053/j.gastro.2014.10.004

Figure 1.

Figure 1

ALV suppresses HBV replication in liver-derived cell lines. HepG2215, HuH-7, and HepaRG cells were treated with 0.25, 1, 5, and 20 μg/mL of ALV and HBV DNA was quantitated by real-time PCR. Cells and supernatants were collected every 24 hours. HepG2215 cells: (A) secreted-virus (SV) HBV DNA and (B) intracellular nucleocapsid-associated (INA) HBV DNA. HuH-7 cells: (C) SV HBV DNA and (D) INA HBV DNA. (E) Southern blot analysis of intracellular HBV DNA from HuH-7 cells. The positions of relaxed circular (RC), double-strand linear (DSL), and single-strand (SS) DNA intermediates are indicated. (F) HepaRG: INA HBV DNA during 7 days (168 hours) of treatment. Mean values and the SD of 3 independent experiments are shown. *P values less than .05, **P values less than .01, and ***P values less than .001 for ALV-treated vs nontreated cells.